Arbutus Biopharma (ABUS) Other Non-Current Liabilities (2011 - 2026)

Arbutus Biopharma has disclosed Other Non-Current Liabilities across 16 years of filings, most recently posting $8.6 million for Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $8.6 million, down 18.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.6 million (down 18.24% YoY), and the FY2025 annual result was $3.4 million, down 66.34% from the prior year.
• Other Non-Current Liabilities came in at $8.6 million for Q1 2026 at Arbutus Biopharma, up from $3.4 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $14.2 million in Q2 2022 to a low of $3.4 million in Q4 2025.
• The 5-year median for Other Non-Current Liabilities is $8.0 million (2024), against an average of $8.1 million.
• Peak annual rise in Other Non-Current Liabilities reached 234.97% in 2022, while the deepest fall reached 81.27% in 2022.
• Arbutus Biopharma's Other Non-Current Liabilities stood at $10.4 million in 2022, then decreased by 26.68% to $7.6 million in 2023, then jumped by 34.54% to $10.2 million in 2024, then tumbled by 66.34% to $3.4 million in 2025, then jumped by 149.97% to $8.6 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $8.6 million (Q1 2026), $3.4 million (Q4 2025), and $3.7 million (Q3 2025), per Business Quant data.